Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Velpanat - 12 weeks

HepatitisC-Natco-Velpatasvir-100mg-Sofosbuvir-400mg-Velpanat

Availability: In stock

Special Price $ 899

BRAND : Velpanat
STRENGTH : 400 mg & 100 mg
INGREDIENT : HepatitisC-Natco-Velpatasvir-100mg-Sofosbuvir-400mg-Velpanat
COMPANY NAME : Natco
COUNT : 28 Tablets



Description of Velpanat - 12 weeks

Velpanat Description: Velpanat is a combination medicine, contains an active ingredients like Sofosbuvir and Velpatasvir, both having anti-viral properties. Velpanat is active against virus which is responsible for chronic hepatitis C viral infection. Velpanat is a prescription medicine; it is used by the patient under the supervision of medical practitioner. Sofosbuvir: HCV NS5B polymerase inhibitor Velpatasvir: HCV NS5A inhibitor Product details: Trade name: Velpanat Active ingredients: Sofosbuvir and Velpatasvir Strength of the drug: 400mg and 100mg respectively Mfg: Natco Package: 28 tablets in a container Category: Anti-viral

Pharmacology of Velpanat - 12 weeks

Velpanat Mechanism of action: Velpanat containing two components which contains antiviral activity, Sofosbuvir is a nucleotide analog, metabolized into uridine analogue triphosphate (GS-461203) it is an active form The metabolite GS-461203 is inserted into hepatitis C virus RNA by NS5B polymerase and performed as a chain terminator. Velpatasvir: NS5A protein is responsible for RNA replication and aggregation of HCV virions. Velpatasvir is a NS5A inhibitor which interfere with the enzyme activity and eradicates the viral multiply Velpanat Pharmacokinetics: 12 weeks Absorption: Absorption of Velpanat occurs very fastly Peak plasma concentration of Sofosbuvir within 1 hour; Velpatasvir 3 hours and active metabolite GS-461203 with 3 hours Distribution: Human plasma protein bound in the range of 61-65% Velpatasvir bound to human plasma protein nearly >99.5% The active metabolite GS-461203 has poor protein binding property Metabolism: Sofosbuvir is largely metabolized in liver, converted to active analogue triphosphate GS-461203 Velpatasvir is eliminated greatly in unchanged form Excretion: 80%, 14%, and 2.5% of the drug is eliminated through urine, faeces and exhaled air respectively. The terminal half life of Tablet Velpanat is 15 hours.

Indication of Velpanat - 12 weeks

Velpanat is primarily indicated for the patients who are suffered with chronic hepatitis C viral infection associated genotype I, II, III, IV, V or VI infection There are two conditions like; Without cirrhosis or with compensated cirrhosis With decompensated cirrhosis with use of ribavirin

Dose & Dosage's of Velpanat - 12 weeks

Velpanat is mainly recommended for adults, safety and efficacy of the drug has not been established for children. Chronic hepatitis C virus (HCV) infection genotypes I, II, III, IV, V or VI One tablet to be taken as a single dose Velpanat should be taken with or without food Without cirrhosis: Velpanat tablets should be taken for 12 weeks Advanced cirrhosis: Velpanat + ribavirin for 12 weeks The dose of ribavirin recommended on the basis of weight of patient; <75 kg: 1000mg/day twice daily ≥75 kg: 1200mg/day twice daily The dosage of ribavirin should be decreased on the basis of hemoglobin and creatine clearance levels. Missed dose: If patient missed the dose of Velpanat tablet, should be skipped and follow the next dose schedule Do not take double dose

Side Effects of Velpanat - 12 weeks

Without cirrhosis Headache, fatigue, shortness of breath, chest pain With decompensated cirrhosis Fatigue, anemia, decreased hemoglobulin levels, nausea, headache, insomnia 1-10% of patients attain; Without cirrhosis; Lipase increase, rash, depression, increased creatine kinase, insomnia, asthenia With decompensated cirrhosis; Diarrhea, hemoglobin levels get depleted, rash, increased creatine kinase

Contraindication of Velpanat - 12 weeks

Velpanat is contraindicated to the pregnant women or become pregnant and children While taking Velpanat with ribavirin causes some defects to the unborn babies

Drug Interaction of Velpanat - 12 weeks

The potentially significant drug interaction occurs while concomitant with some medicines; Acid reducing agents like Aluminium and magnesium hydroxide, H2 receptor antagonist like famotidine, proton pump inhibitors like Omeprazole these drugs are reduce the effect of concentration of Velpatasvir Antiarrhythmic drug like amiodarone when co administered with Velpanat leads to life threatening condition like symptomatic bradycardia While concomitant with digoxin, the effect of concentration of digoxin will get elevated Anticancer drug like topotecan, co administration is not recommended because of elevation of effect of concentration of topotecan Some list of medicines causes drug interactions like; Carbamazepine, phenytoin, Phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, efavirenz, st. Johns wort, rosuvastatin and Atorvastatin

Precaution of Velpanat - 12 weeks

Care should be taking while using Velpanat with ribavirin, amiodarone causes; Serious effects to unborn baby Bradycardia respectively Patient with liver and kidney disorders

Usage & Safety profile of Velpanat - 12 weeks Pregnancy & Lactation

Generally, Velpanat is not prescribed for pregnant women and who become pregnant and children Velpanat with ribavirin is contraindicated to pregnant women it may cause fetal death In lactation, some metabolites are excreted in human milk it also cause some ill effects

Storage of Velpanat - 12 weeks

Velpanat should be stored at room temperature. Velpanat container should be keep away from moisture, heat, and light